Total Shareholder Return

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A Miami investment firm made a massive 3.86x return in 8 months by betting that power, not chips, was the real constraint on the AI industry's growth.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The South Korean tobacco giant hits record revenue as its international strategy pays off, while it diversifies into nicotine pouches for future growth.